MPS I: Hematopoietic Stem Cell Transplantation and Enzyme Replacement Therapy

Hematopoietic stem cell transplantation (HSCT) in children with MPS I involves replacing their deficient macrophages with ones that produce normal amounts of enzyme. [Weisstein: 2004] [Souillet: 2003] [Gassas: 2003] The success rate of HSCT depends upon several factors, such as the age of the patient and degree of pulmonary involvement at time of transplant. Successful HSCT increases survival, reduces facial coarseness and hepatosplenomegaly, improves hearing, and maintains normal heart function; however the skeletal manifestations and corneal clouding continue to progress unabated.
Neuropsychological responses to HSCT are related to the age and intellectual capacity of the child at the time of the engraftment. If HSCT is done before evidence of significant developmental delay (usually under 2 years), there is some success in decreasing the degree and rate of cognitive decline. Children showing significant cognitive impairment prior to undergoing HSCT do not appear to benefit developmentally. As with any HSCT, there is a risk of graft-versus-host disease and up to a 20% risk of mortality. The use of ERT before HSCT might improve the clinical signs and symptoms (i.e. severe cardiomyopathy) resulting in less transplantation-related complications. [Cox-Brinkman: 2006]
Enzyme replacement therapy (ERT) involves intravenous administration of recombinant alpha-L-iduronidase enzyme (Aldurazyme) to assist in the breakdown of accumulated storage and prevent further buildup. [Muenzer: 2004] [Wraith: 2005] [Wraith: 2004] Significant reduction in liver size, increase in height and weight, decrease in joint restriction, and improvement in breathing and sleep apnea were demonstrated in individuals with attenuated MPS I. The benefit of ERT in those with severe disease has not been assessed. Because the recombinant enzyme is not thought to cross the blood-brain barrier, the best option to reduce the risk of cognitive impairment remains HSCT initiated early. As with HSCT, ERT does not appear to have significant beneficial effects on bone disease or corneal clouding.
The current dose regimen involves premedication with anti-inflammatory and antihistamine drugs and intravenous weekly infusion of 100 units (0.58 mg)/kg of Aldurazyme over four hours. Although antibodies were present in all study patients in the clinical trials, no known clinical consequences have been reported. Volumetric CT scan of liver and spleen can be used as an objective measure of the efficacy of enzyme replacement therapy during the first few months of treatment.
Unlike the use of elaprase enzyme replacement therapy for Hunter syndrome (MPS II), the use of intrathecal administration of aldurazyme is not clinically available and requires reformulation of the enzyme preparation as it is not compatible with CSF and intrathecal membranes.



Pediatric Genetics

We currently have no Pediatric Genetics service providers listed; search our Services database for related services.

Pediatric Hematology/Oncology

See all Pediatric Hematology/Oncology services providers (11) in our database.

For other services related to this condition, browse our Services categories or search our database.



MPS I Registry
An ongoing, observational database that tracks natural history and outcomes of patients with MPS I. The Registry was initiated worldwide in April 2003 as an international observational program sponsored by BioMarin/Genzyme LLC and administered by Genzyme Corporation. Registration is voluntary, free, and confidential.


Content Last Updated: 11/2011

Page Bibliography

Cox-Brinkman J, Boelens JJ, Wraith JE, O'meara A, Veys P, Wijburg FA, Wulffraat N, Wynn RF.
Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome.
Bone Marrow Transplant. 2006;38(1):17-21. PubMed abstract

Gassas A, Sung L, Doyle JJ, Clarke JT, Saunders EF.
Life-threatening pulmonary hemorrhages post bone marrow transplantation in Hurler syndrome. Report of three cases and review of the literature.
Bone Marrow Transplant. 2003;32(2):213-5. PubMed abstract

Muenzer J, Fisher A.
Advances in the treatment of mucopolysaccharidosis type I.
N Engl J Med. 2004;350(19):1932-4. PubMed abstract

Souillet G, Guffon N, Maire I, Pujol M, Taylor P, Sevin F, Bleyzac N, Mulier C, Durin A, Kebaili K, Galambrun C, Bertrand Y, Froissart R, Dorche C, Gebuhrer L, Garin C, Berard J, Guibaud P.
Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources.
Bone Marrow Transplant. 2003;31(12):1105-17. PubMed abstract

Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S.
Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation.
J Pediatr Orthop. 2004;24(1):97-101. PubMed abstract

Wraith JE.
The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.
Expert Opin Pharmacother. 2005;6(3):489-506. PubMed abstract

Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF.
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
J Pediatr. 2004;144(5):581-8. PubMed abstract